Ensysce Biosciences

About:

Ensysce Biosciences is a clinical-stage biotech company that develops tamper-proof prescription drugs to minimize abuse and overdose risks.

Website: http://www.ensysce.com

Twitter/X: EnsysceBio

Top Investors: National Institutes of Health, National Institute on Drug Abuse (NIDA), The Global Emerging Markets Group, Texas Wide Open for Business

Description:

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company uses a proprietary technology platform to create abuse-resistant opioids and overdose-protection products, aiming to reduce the risk of addiction and accidental overdose associated with traditional opioids. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms, the company is in the process of developing a new class of tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.